Here's Why GSK (GSK) is a Strong Value Stock
https://www.zacks.com/stock/news/2232453/here-s-why-gsk-gsk-is-a-strong-value-stock?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2232453
Feb 27, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
GSK (GSK) Stock Declines While Market Improves: Some Information for Investors
https://www.zacks.com/stock/news/2234243/gsk-gsk-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2234243
Feb 29, 2024 - In the most recent trading session, GSK (GSK) closed at $41.90, indicating a -1.04% shift from the previous trading day.
0
Top Research Reports for Adobe, United Parcel & Deere
https://www.zacks.com/commentary/2237064/top-research-reports-for-adobe-united-parcel-deere?cid=CS-ZC-FT-research_daily-2237064
Mar 07, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), United Parcel Service, Inc. (UPS) and Deere & Company (DE).
0
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
https://www.zacks.com/stock/news/2240226/allogene-allo-inks-deal-with-arbor-bio-for-crispr-technology?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240226
Mar 13, 2024 - Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.
0
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446
Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
0
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
https://www.zacks.com/stock/news/2242368/immuneering-imrx-plummets-71-in-one-week-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2242368
Mar 18, 2024 - Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
0
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035
Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
0
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
https://www.zacks.com/stock/news/2243568/gsk-outperforms-industry-on-strength-in-key-drugs-vaccines?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2243568
Mar 20, 2024 - Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
0
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405
Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
0
GSK or TECH: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2245610/gsk-or-tech-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2245610
Mar 25, 2024 - GSK vs. TECH: Which Stock Is the Better Value Option?
0